

Sequence Listing

<110> AKESO BIOPHARMA, INC.

<120> MONOCLONAL ANTIBODY AGAINST NERVE GROWTH FACTOR, AND ENCODING GENE AND USE THEREOF

<160> 10

<170> SIPOSequenceListing 1.0

<210> 1

<211> 363

<212> DNA

<213> Nucleotide sequence of the heavy chain variable region of monoclonal antibody H26L17 (Artificial Sequence)

```
<400> 1
caggtgcagc tgcaggaaag cggaccagga ctggtgaagc ctagcgagac cctgagcctg      60
acttgtaccg tgtccgatt cgatctgagc ggctacgacc tgaattggat cagacagcct      120
cccggaaaag gcctggagt gatcggtatc gtctggggag acggcagcag cgattacaac      180
agcgccgtga agagccgcgt gacaatcagc aaggacacca gcaagaacca gttcagcctg      240
aagctgtcta gcgtgacagc cgccgataca gcagtgtact attgcgtgcg gggcggctat      300
tggtacgcca ccagctacta cttcgactat tggggccagg gaacactggg gaccgtgtct      360
tct                                         363
```

<210> 2

<211> 121

<212> PRT

<213> Amino acid sequence of the heavy chain variable region of monoclonal antibody H26L17 (Artificial Sequence)

```
<400> 2
Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1      5      10      15
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Phe Asp Leu Ser Gly Tyr
20     25     30
Asp Leu Asn Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile
35     40     45
Gly Ile Val Trp Gly Asp Gly Ser Ser Asp Tyr Asn Ser Ala Val Lys
50     55     60
Ser Arg Val Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Phe Ser Leu
65     70     75     80
Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Val
85     90     95
Arg Gly Gly Tyr Trp Tyr Ala Thr Ser Tyr Tyr Phe Asp Tyr Trp Gly
100    105    110
Gln Gly Thr Leu Val Thr Val Ser Ser
115    120
```

<210> 3

<211> 321

<212> DNA

<213> Nucleotide sequence of the light chain variable region of monoclonal antibody H26L17 (Artificial Sequence)

```
<400> 3
gatatccaga tgaccagag ccccagctct ctgtcagcca gcgtgggcca tagagtgacc      60
atcacttgca gagccagcga gagcatcagc agcaacctga attggtacca gcagaagcca      120
ggcaaggccc ccaagctgct gatctactac accagcagat tccacagcgg cgtgcctagc      180
agattcagcg gaagcggcag cggcaccgac ttacaccttca ccatcagctc tctgcagccc      240
gaggacatcg ccacctaata ttgccagcag gagcacaccc tgccctttac ctttggccag      300
ggaacaaagc tggagatcaa g                                         321
```

<210> 4

<211> 107

<212> PRT

<213> Amino acid sequence of the light chain variable region of monoclonal

antibody H26L17 (Artificial Sequence)

```

<400> 4
Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1 5 10 15
Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Glu Ser Ile Ser Ser Asn
20 25 30
Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
35 40 45
Tyr Tyr Thr Ser Arg Phe His Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Asp Phe Thr Phe Thr Ile Ser Ser Leu Gln Pro
65 70 75 80
Glu Asp Ile Ala Thr Tyr Tyr Cys Gln Gln Glu His Thr Leu Pro Phe
85 90 95
Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys
100 105

```

```

<210> 5
<211> 8
<212> PRT
<213> Heavy chain variable region complementarity determining region 1 (HCDR1)

```

```

<400> 5
Gly Phe Asp Leu Ser Gly Tyr Asp
1 5

```

```

<210> 6
<211> 7
<212> PRT
<213> Heavy chain variable region complementarity determining region 2 (HCDR2)

```

```

<400> 6
Val Trp Gly Asp Gly Ser Ser
1 5

```

```

<210> 7
<211> 15
<212> PRT
<213> Heavy chain variable region complementarity determining region 3 (HCDR3)

```

```

<400> 7
Val Arg Gly Gly Tyr Trp Tyr Ala Thr Ser Tyr Tyr Phe Asp Tyr
1 5 10 15

```

```

<210> 8
<211> 6
<212> PRT
<213> Light chain variable region complementarity determining region 1 (LCDR1)

```

```

<400> 8
Glu Ser Ile Ser Ser Asn
1 5

```

```

<210> 9
<211> 3
<212> PRT
<213> Light chain variable region complementarity determining region 2 (LCDR2)

```

```

<400> 9
Tyr Thr Ser
1

```

```

<210> 10
<211> 9
<212> PRT
<213> Light chain variable region complementarity determining region 3 (LCDR3)

```

<400> 10
Gln Gln Glu His Thr Leu Pro Phe Thr
1 5